J&J, Amgen Scrutinized For Anemia Drug Marketing

Law360, New York (April 2, 2008, 12:00 AM EDT) -- Congressional leaders have asked Johnson & Johnson and Amgen Inc. to turn over records related to the advertising and marketing of their anemia drugs amid reports of increased risks of blood clots and death when used in high doses.

Rep. John Dingell (D-Mich.), the chairman of the House Energy and Commerce Committee, and Rep. Bart Stupak (D-Mich.), chairman of the subcommittee of Oversight and Investigations, said in letters dated Tuesday that they were concerned with the ways the companies marketed the treatments, Procrit, Aranesp and Epogen,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.